Hoba Therapeutics ApS: Financial statements 2019
CVR: 38231170
Source: annual report 2019, Danish Business Authority
01/04/2018 – 31/03/2019
Hoba Therapeutics ApS (CVR 38231170) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK 296,143 and a net result of DKK -1,145,346 compared with DKK -891,853 the year before. That is a decrease of 39% compared with the year before. Equity in the 2019 report amounted to DKK 11,710,435. The solvency ratio was 75.5%.
- Gross Profit
- DKK 296,143
- Profit/Loss
- DKK -1,145,346
- Equity
- DKK 11,710,435
- Total Assets
- DKK 15,505,029
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningAbout Hoba Therapeutics ApS
Hoba Therapeutics ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Gonçalo Nuno Nunes da Silva Rebelo de Andrade. The board consists of Gonçalo Nuno Nunes da Silva Rebelo de Andrade (chair) and Gunnar Magnus Severus Modée Persson. The company's owners include Novo Holdings A/S, Danmarks Eksport- og Investeringsfond and EIC Fund. The company has 2 employees (2026). In 2026, the company reported a gross profit of DKK -61,710,701 and a net result of DKK -67,693,868 compared with DKK -43,008,287 the year before. Equity in the 2026 report amounted to DKK 1,143,899.
